Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 41Non-Muscle Invasive Bladder Neoplasms 25Colorectal Neoplasms 20Anus Neoplasms 17Carcinoma, Transitional Cell 15Neoplasm Metastasis 12Carcinoma, Hepatocellular 10Appendiceal Neoplasms 10Stomach Neoplasms 9Peritoneal Neoplasms 9Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Lung Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 5Liver Neoplasms 5Sarcoma 4Anal Canal Carcinoma 4Urologic Neoplasms 3Urologic Diseases 3Urinary Bladder Diseases 3Pseudomyxoma Peritonei 3Mesothelioma, Malignant 3Gastrointestinal Neoplasms 3Carcinoma in Situ 3Carcinoma 3Breast Neoplasms 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Standard of Care 2B701 protein, Human herpesvirus 6 2valrubicin 1trifluridine tipiracil drug combination 1testosterone 17 beta-cypionate 1palbociclib 1enfortumab vedotin 1atezolizumab 1Water 1Valsartan 1Urinary Diversion 1Tranexamic Acid 1Testosterone Propionate 1Sunitinib 1Stents 1Radiosurgery 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1Nephrotomy 1Nephrostomy, Percutaneous 1Methyltestosterone 1Immune Checkpoint Inhibitors 1Ice 1Hydroxychloroquine 1Health Information Exchange 1Gemcitabine 1Gels 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Urologic Diseases × Mitomycin × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT01200992 2017-08-24

EMBARC-RF

Bioniche Life Sciences Inc.

Phase 3 Terminated
84 enrolled 7 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡